The global cemiplimab rwlc market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The cemiplimab injection is used to treat several types of CSCC that spread to nearby tissues and cannot be treated with surgery or radiation therapy. The rise in the incidence of basal cell carcinoma (BCC) is one of the major drivers for the growth of the global cemiplimab rwlc market. For instance, according to the data published by National Center for Biotechnology Information in 2021, BCC is the most common skin cancer in humans, with increasing incidence rates globally. Further, BCC is the most common in locations with greater UV exposure. Moreover, since the last 30 years, the estimated prevalence rates have risen from 20.0% to 80.0%. The incidence rate also increases with an increase in age, with the median age of diagnosis being 68 years. Also, the male gender is expected to have a high risk of mortality at twice the rate compared with women.
According to the data published by the Skin Cancer Foundation in 2019, is the most common form of skin cancer which is 5 times more prevalent than melanoma in the US. As per the same source, 1.8 million cases are diagnosed annually and 40000 cases are progressed to the advanced stage when cancer spreads and becomes difficult to treat. Moreover, the skin cancer foundation in coordination with Regeneron and Sanofi conducted a survey in 2019, which revealed 3 in 4 Americans (74.0%) are unaware of CSCC and 3.0% of Americans identified CSCC as a common type of cancer. Thus, the rise in the prevalence of CSCC across the globe is anticipated to drive the cemiplimab rwlc market global.
Looking towards the demand for cemiplimab rwlcs key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Sanofi had received the USFDA approval for PD-1 inhibitor Libtayo (cemiplimab rwlc) as immunotherapy indicated for patients with advanced basal cell carcinoma(BCC) previously treated with hedgehog pathway inhibitor (HHI), and accelerated approval was granted for patients with metastatic BCC. Further, in November 2021, Verrica Pharmaceuticals Inc. has announced the USFDA acceptance for the company’s Investigational New Drug Application (IND) for LTX-315, used for the treatment of basal cell carcinoma. Moreover, the company is anticipated to initiate its phase-2 trials in the first quarter of 2022.
In June 2020, Merck &Co. had received USFDA approval for Pembrolizumab for the treatment of patients with recurrent or metastatic CSCC that is not curable by surgery or radiation therapy. Thus, such product launches and approvals are anticipated to drive the growth of the global cemiplimab rwlc market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Cemiplimab rwlc Market at https://orionmarketreports.com/request-sample/?id=92677&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape– Merck & Co., Novartis International AG, and Sanofi SA among others.
A full report is available at: https://orionmarketreports.com/global-cemiplimab-rwlc-market/92677/
Global Cemiplimab rwlc Market Report by Segment
By Type
- 350mg Injection
- Type2
By Application
- Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
- Locally Advanced CSCC
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
